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Abstract: Multiple sclerosis (MS) is characterized by pro-inflammatory cytokine production.
Acetylcholine (ACh) contributes to the modulation of central and peripheral inflammation.
We studied the homeostasis of the cholinergic system in relation to cytokine levels in immune cells and
sera of relapsing remitting-MS (RR-MS) patients. We demonstrated that lower ACh levels in serum
of RR-MS patients were inversely correlated with the increased activity of the hydrolyzing enzymes
acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). Interestingly, the expression of the
ACh biosynthetic enzyme and the protein carriers involved in non-vesicular ACh release were found
overexpressed in peripheral blood mononuclear cells of MS patients. The inflammatory state of the
MS patients was confirmed by increased levels of TNFα, IL-12/IL-23p40, IL-18. The lower circulating
ACh levels in sera of MS patients are dependent on the higher activity of cholinergic hydrolyzing
enzymes. The smaller ratio of ACh to TNFα, IL-12/IL-23p40 and IL-18 in MS patients, with respect to
healthy donors (HD), is indicative of an inflammatory environment probably related to the alteration
of cholinergic system homeostasis.
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1. Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS)
characterized by the presence of sclerotic plaques that impair correct neuronal signal transmission [1].
Although the aetiology is still unclear, it is widely accepted that MS is caused by T cell auto-reactivity.
In fact, these cells recognize some myelin like-proteins as “non-self”, causing the spread of an
inflammatory response in the brain and spinal cord, leading to the destruction of myelin sheets.
Cytokines, the major regulators of the immune system, play a key role in modulating the
inflammatory cascade in MS. Previous studies in MS patients and experimental animal models
have highlighted that MS is mediated by Th1-type immune responses. IL-12 and IL-23 promote
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the development of Th1-type immune responses affecting the synthesis of several other cytokines
including TNFα and IFNγ. Increased expression of IL-12p40 detected in acute MS plaques confirmed
the pathogenic role for IL-12 in MS [2]. Together with IL-12, IL-18 acts as a link between innate and
adaptive immune responses and participates in the pathogenesis of MS [3].
Acetylcholine (ACh), a classical neurotransmitter of the nervous system, can act as an
immunomodulatory signal [4]. In immune cells, ACh is synthesized by the choline acetyltransferase
(ChAT) enzyme [5]. The steady-state equilibrium of ACh is due to the action of two degradative
enzymes: AChE, a specific cholinesterase that hydrolyzes selectively ACh, and BuChE, a non-selective
cholinesterase that is able to hydrolyze ACh, in particular when co-expressed in ChAT-positive
neurons localized in selected areas of the spinal cord and medulla oblongata [6]. Interestingly,
studies in AChE-knockout mice have also indicated that BuChE is able to compensate for the AChE
absence in ACh hydrolysis [7]. AChE is most abundant in the nervous system where ACh is rapidly
hydrolyzed at the cholinergic synapses. BuChE is largely expressed both in the nervous system and in
other tissue including blood, and its altered levels correlate with different neurological diseases [8].
The ACh storage mechanism is not yet clear, as the lymphocytes do not express vesicular acetylcholine
transporter (VAChT) [9]. So it is likely that the ACh is synthesized and probably released through
a non-vesicular release mechanism. In fact the expression of mediatophore and organic cationic
membrane transporter novel type 1 (OCTN-1) appear to be involved in non-vesicular acetylcholine
release in different tissues including the immune cells [10–12].
Recent reports have demonstrated a direct link between inflammation and the cholinergic system.
In fact, through “neuronal” and “non-neuronal cholinergic anti-inflammatory pathways”, mediated
by the vagus nerve and immune cells respectively, ACh actively participates in the modulation of
cytokine synthesis and release [13–15]. The cholinergic muscarinic and nicotinic receptors mediate
ACh functions in immune cells modulating the release of pro- and anti-inflammatory cytokines,
respectively [11].
Considering this immuno-regulatory effect of ACh, it appears interesting to evaluate the role of
the cholinergic system in MS. Previously we demonstrated that ACh levels in sera and cerebrospinal
fluid (CSF) of RR-MS patients was lower than in HD [16]. Moreover, alterations of cholinesterase
activities have been described in the nervous system, in sera and in plasma of MS patients [17,18].
Albeit cholinergic alterations being described in MS, a complete analysis of all cholinergic system
members in the immune cells of MS patients, as well as an analysis demonstrating the co-presence
of ACh and its hydrolyzing enzymes, is, at least, lacking. Similarly, the co-presence of peripheral
cytokine levels and cholinergic markers in MS patients remains poorly investigated. In this context,
we evaluated the expression and the activity of the cholinergic biosynthetic and degradative enzymes
in sera and in peripheral blood mononuclear cells (PBMC) of RR-MS patients in relation to circulating
ACh levels. The expression of two cholinergic membrane transporters involved in ACh release in
biological fluids (i.e., mediatophore and OCTN-1) has been also evaluated. Finally the possible
correlation of cholinergic marker expression and pro-inflammatory cytokine levels (i.e., IL-12/IL-23,
IL-18 and TNFα) has been also estimated.
2. Results
2.1. ACh Levels and AChE and BuChE Activity in Sera of RR-MS Patients
In this study we have confirmed the results obtained in our previous study on a small number of
subjects [16]. As reported in Figure 1A, the ACh levels measured in the serum of the new extended
group of 87 RR-MS patients were significantly lower, about four times, than in 60 HD. In order to
evaluate whether the lower levels of ACh were dependent on a defect in ACh synthesis and/or
hydrolysis, first of all, in the same RR-MS patients and HD subjects we evaluated the activity of
the ACh hydrolyzing enzymes AChE and BuChE. The enzymatic activity resulted in significantly
higher levels for both enzymes in sera of MS patients as compared to HD (Figure 1B,C). A negative
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correlation, although not statistically significant, between levels of ACh and AChE and BuChE activity
was observed (Table 1, Figure 1).Int. J. Mol. Sci. 2016, 17, 2009 3 of 11 
 
 
Figure 1. Cholinergic marker levels in serum of RR-MS patients and HD. (A) ACh levels (pmol/mL); 
(B) AChE activity (mU/mL); (C) BuChE activity (mU/mL). The bars represent the standard error  
(p-values reported in figure are relative to comparison between groups). 
Table 1. Spearman Rho correlation coefficient (relative p-value) of ACh levels vs. cholinergic markers. 
Cholinergic Markers RR-MS Group HD Group
AChE −0.121 (0.334) −0.118 (0.411) 
BuChE −0.122 (0.327) −0.112 (0.432) 
OCTN-1 0.239 (0.323) −0.135 (0.661) 
Mediatophore −0.059 (0.810) −0.171 (0.576) 
ChAT −0.249 (0.319)  
2.2. Cholinergic Marker Expression in PBMC of RR-MS Patients 
In order to evaluate whether the enhancement of cholinesterase activity depends on the 
increased expression of these enzymes, we analyzed the expression of AChE and BuChE transcripts 
in total RNA extracted by PBMC in a group of RR-MS patients (n = 15) and HD (n = 15) using  
qRT-PCR. Although we observed a high inter-individual variability, especially in the RR-MS group, 
the increase of the transcript levels of both hydrolyzing enzymes is evident, in particular for BuChE 
(Figure 2A,B). To verify if the ACh-synthesizing enzyme may upload the steady-state equilibrium of 
ACh levels, balancing the actions of higher cholinesterases, in RR-MS patients and HD subjects we 
Figure 1. Cholinergic marker levels in serum of RR-MS patients and HD. (A) ACh levels (pmol/mL);
(B) AChE activity (mU/mL); (C) BuChE activity (mU/mL). The bars represent the standard error
(p-values reported in figure are relative to comparison between groups).
Table 1. Spearman Rho correlation coefficient (relative p-value) of ACh levels vs. cholinergic markers.
Cholinergic Markers RR-MS Group HD Group
AChE −0.121 (0.334) −0.118 (0.411)
BuChE −0.122 (0.327) −0.112 (0.432)
OCTN-1 0.239 (0.323) −0. 35 (0.661)
Mediatophore −0. 59 (0.810) −0.171 (0.576)
ChAT −0.249 (0.319)
2.2. Cholinergic Marker Expression in PBMC of RR-MS Patients
In order to evaluate whether the enhancement of cholinesterase activity depends on the increased
expression of these enzymes, we analyzed the expression of AChE and BuChE transcripts in total RNA
extracted by PBMC in a group of RR-MS patients (n = 15) and HD (n = 15) using qRT-PCR. Although we
observed a high inter-individual variability, especially in the RR-MS group, the increase of the transcript
levels of both hydrolyzing enzymes is evident, in particular for BuChE (Figure 2A,B). To verify if
the ACh-synthesizing enzyme may upload the steady-state equilibrium of ACh levels, balancing the
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actions of higher cholinesterases, in RR-MS patients and HD subjects we evaluated the expression
of the transcript for the ACh biosynthetic enzyme choline acetyltransferase (ChAT). As reported in
Figure 2C, the levels of ChAT mRNA were higher in MS patients compared with HD subjects. Moreover,
the analysis of the transcript for OCTN-1 and mediatophore, the two proteins responsible for the
non-vesicular ACh release, typically expressed in immune cells [10,11], indicated higher OCTN-1
expression in PBMC of MS patients (Figure 3A,B), while the expression of mediatophore did not appear
significantly changed (Figure 3A,C).
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Figure 3. Expression of cholinergic markers in PBMC of RR-MS and HD. (A) A representative  
RT-PCR analysis of mediatophore and OCTN-1 performed in MS patients and HD; (B) densitometric 
analysis of the bands of OCTN-1 expressed in RR-MS and HD (n = 15); (C) densitometric analysis of 
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Figure 2. Analysis by qRT-PCR of cholinergic marker expression in PBMC of RR-MS and HD.
Expression of AChE (A); BuChE (B) and ChAT transcript (C) levels. Further, 18S was used as
housekeeping gene. The bars represent the standard error (p-values reported in figure are relative to
comparison between groups).
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Figure 3. Expression of cholinergic markers in PBMC of RR-MS and HD. (A) A representative RT-PCR
analysis of mediatophore and OCTN-1 performed in MS patients and HD; (B) densitometric analysis
of the bands of OCTN-1 expressed in RR-MS and HD (n = 15); (C) densitometric analysis of the bands
of m di tophore xpressed in RR-MS and HD (n = 15). The bars repres nt the standard error (p-values
repo ted in figure are r lative to comparison between groups).
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2.3. Expression of IL-12/IL-23p40, IL-18 and TNFα
We also evaluated serum levels of TNFα and of two cytokines involved in Th1 commitment
such as IL-12p40, the common subunit shared by IL-12, IL-23 and IL-18. Significant differences in
circulating levels of TNFα, IL-12/IL-23p40 and IL-18 were observed between RR-MS patients and HD
(Figure 4A–C). To evaluate whether the serum cytokine levels could be related to production by PBMC,
we also evaluated the spontaneous expression of selected cytokines in PBMC isolated from MS patients
and HD subjects. Significantly higher mRNA levels of IL-18 were constitutively expressed in PBMC
of MS patients with respect to HD subjects; IL-12/IL-23p40 and TNFα, although not significantly so,
were higher in RR-MS than in HD (Figure 4D–F).
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Figure 4. Cytokine levels in serum of RR-MS and HD. (A) IL-18 levels (pg/mL); (B) IL-12/IL-23p40
levels (pg/mL); (C) TNFα levels (pg/mL). Cytokine expression in PBMC of RR-MS and HD; (D) IL-18;
(E) IL-12/IL-23p40; (F) TNFα 18S was used as housekeeping gene. The bars represent the standard
error (p-values reported in figure are relative to comparison between groups).
2.4. Relationship between Cholinergic Markers and Cytokine Levels
Since previous studies have hypothesized that ACh acts as a suppressor inflammatory responses
of lymphocytes [4], we have investigated the interrelationship of ACh generating and degrading
enzymes and pro-inflammatory cytokines in MS patients and HD subjects. We found that AChE levels
increased by >60% and BuChE levels increased by >40%, resulting in an overall decrease in ACh of
65% in MS patients compared to HD. Thus, AChE and BuChE, present at high levels in MS patients,
alter the steady-state equilibrium of ACh and the ratio of AChE and BuChE to ACh was higher in
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MS patients than in HD (AChE/ACh 3.6 vs. 0.7, p < 0.001, and BuChE/ACh 13.0 vs. 3.1, p < 0.001).
Although a non-significant association between ACh-hydrolyzing enzymes and IL-18, IL-12/IL-23p40
and TNFα levels was found, the smaller ratio of ACh to cytokines in RR-MS patients compared to HD
(p < 0.001) is indicative of an inflammatory environment (Table 2).
Table 2. Mean and standard error of ratio between ACh/cholinergic hydrolyzing enzymes and
ACh/cytokines.
Ratio RR-MS Group HD Group p-Value a
AChE/ACh 3.6 ± 0.3 0.7 ± 0.1 <0.001
BuChE/ACh 13.0 ± 0.4 3.1 ± 0.1 <0.001
ACh/TNFα 8.9 ± 1.8 140.6 ± 14.9 <0.001
ACh/IL-18 0.5 ± 1.9 5.0 ± 0.3 <0.001
ACh/IL-12/IL-23p40 0.6 ± 0.2 5.6 ± 0.5 <0.001
ACh/TNFα mRNA 291.1 ± 16.7 863.6 ± 15.8 <0.001
ACh/IL-18 mRNA 1007.5 ± 0.2 2038.0 ± 1.1 <0.001
ACh/IL-12/IL-23p4 mRNA 1019.0 ± 0.5 3022.5 ± 0.5 <0.001
a Mann-Whitney U test.
3. Discussion
MS is a chronic inflammatory immune-mediated disease of the CNS [19] accompanied by severe
peripheral and central inflammation responsible for myelin destruction and axon degeneration.
The dysfunctions in the immune system in terms of antibodies and cytokine production are intimately
related to the nervous system alterations; therefore, the control of the peripheral inflammation may
contribute to ameliorate the central inflammation and to recover the nervous system functions [20].
The role of ACh in the pathogenesis of human diseases is emerging [21] and its involvement
in cancer and various autoimmune pathologies has been, however, poorly investigated. Moreover,
different nervous system disorders are characterized by cholinergic alterations that may be responsible
for the increased inflammatory processes in the brain [22,23].
In fact, ACh is involved in the immune system functions regulating pro- and anti-inflammatory
cytokine production and release (through muscarinic and nicotinic receptor activation, respectively) [24,25]
and modulating B cells antibody production [26]. Current knowledge of cholinergic system activity
in MS is quite limited. In experimental autoimmune encephalomyelitis mice (EAE), the main MS
animal model, the use of AChE inhibitors causes a significant reduction of CNS lymphocyte infiltrates,
confirming a role for ACh even in the modulation of central nervous system inflammation [15,27].
Our previous study has indicated that the ACh levels were significantly decreased in sera and
CSF of RR-MS patients, suggesting a deficiency in the cholinergic system in MS [16]. In the present
study, first of all, we have confirmed in a larger number of patients that ACh levels were significantly
reduced in sera of RR-MS subjects, and, in order to better understand the involvement of ACh in
the pathogenesis of MS, we have investigated the possible causes responsible for decreased ACh
levels. To clarify if the possible cause of lower ACh levels was the increased hydrolysis or a decreased
synthesis or release of ACh, we have analyzed the expression and the activity of the hydrolyzing
enzymes AChE and BuChE. Interestingly the cholinesterase activity appeared significantly enhanced
in sera of RR-MS patients compared to HD. This activity is dependent on the soluble form of AChE
released in serum; in fact, the presence of the G4 form of AChE has been reported in human serum [28].
Although a complete characterization of the AChE molecular forms produced by hematopoietic
cells is still lacking, it is known that all the immune cells (erythrocytes, platelets, lymphocytes and
monocytes/macrophages) produce and release AChE in particular in stress conditions [29,30]. In the
PBMC of the same MS patients, the activity is accompanied by an increase in AChE and BuChE
transcripts. Several authors have hypothesized that variations in post-transcriptional mechanisms (i.e.,
microRNAs) regulating the levels of these cholinesterase may contribute to their altered expression [31].
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In order to exclude that reduced ACh levels in serum may dependent also on deficiency in
synthesis and release, we have evaluated the expression of the ACh biosynthetic enzyme, ChAT, and of
the non-vesicular ACh transporters OCTN-1 and mediatophore [10,32] in RR-MS patients. The data
obtained have indicated that both ChAT and OCTN-1 transcripts are significantly increased in RR-MS
patients compared to HD, while mediatophore expression appears substantially unchanged. Our data
demonstrate that all cholinergic components necessary for the synthesis and release of ACh are not
defective in MS patients. However, we suggest that in MS patients, changes in the expression of
AChE and BuChE would alter the availability of ACh and then this may lead to upregulation of ChAT
and OCTN-1 expression in order to try to upload steady-state equilibrium of ACh levels. Further
studies are needed to clarify if the increased transcript levels of ChAT and OCTN-1 were related
to an up-regulation of the respective proteins. Altogether, our findings support the idea that the
cholinergic dysfunction described in MS patients should be directly related to increased levels of
ACh-degradative enzymes.
Th1-mediated responses are involved in the pathogenesis of MS and the Th1/Th2 paradigm
has been useful in understanding the mechanism of immunomodulatory therapies. Thus, in our
MS patients we have analyzed the levels of IL-18, a co-stimulant for Th1 cytokine production, IL-12,
which plays a key role in Th1 differentiation, and TNFα production. In accordance with our previous
study [16], we showed that the higher levels of pro-inflammatory cytokines IL-1β and IL-17 are related
to decreased ACh levels, suggesting that ACh alteration may modulate IL-17 production or Th17 cell
activation [16]. Interestingly, in the present study we found that in MS patients, increased BuChE
and AChE activity matches with higher levels of IL-18, IL-12/IL-23p40 and TNFα. Our findings are
consistent with studies on animal models for MS showing the amelioration of EAE after treatment
with antibody against IL-12/IL-23p40 [33,34], and with the involvement of TNF in demyelinating
disease [35]. The high serum levels of TNFα, IL-18 and IL-12/IL-23p40 are indicative of Th1 activation
and an inflammatory environment. On the other hand, ACh levels allow us to hypothesize that the
inability of RR-MS patients to promptly counteract the inflammation and the altered immune response
should not be dependent either on a defect of ACh synthesis and release, or on the lack of activity
and expression of nicotinic receptors. In fact, in our previous work we have demonstrated that the
α-7 nicotinic receptors are expressed in PBMC of RR-MS patients and their stimulation can negatively
modulate pro-inflammatory cytokines [36]. Our results, in agreement with previous observations
indicating altered levels of cholinesterases in serum, plasma and CSF of MS patients [18], may explain
why the use of cholinesterase inhibitors could decrease the release of pro-inflammatory cytokines,
reduce neuro-inflammation, ameliorate EAE symptoms and improve cognitive deficit [37,38].
4. Materials and Methods
4.1. Subjects
Relapsing Remitting-MS patients were enrolled and followed at Department of Neuroscience of
San Camillo-Forlanini Hospital (Rome, Italy). The diagnosis of RR-MS was confirmed according to
revised Mc Donald Diagnostic Criteria [39] and RR-MS course was established by clinical parameters
in agreement with recent classification [40]. Healthy donors (HD) were enrolled from the Transfusion
Blood Bank Services of Chieti (Chieti, Italy) and were matched for age and gender. Mean age, mean
disease duration and mean Expanded Disability Status Scale (EDSS) are shown in Table 3. The BBB
impairment, refers to the ratio between CSF albumin/serum albumin, and represent an index of the
functional alteration of the blood-brain barrier (BBB). All patients and HD signed an informed consent.
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Table 3. Characteristics of the subjects involved in this study.
Variable HD Group (n = 60) RR-MS Group (n = 87) p-Value
Gender, n (%) 0.601 a
Male 7 (11.7) 21 (16.7)
Female 53 (88.3) 66 (83.3)
Age (years), median (range) 41 (19–66) 38 (18–59) 0.377 b
BBB impairment, median (range) - 5.5 (2.8–15.2)
Duration of disease (years), median (range) - 5 (3–6)
EDSS, median (range) - 2.5 (0.0–6.0)
BBB: blood-brain barrier; EDSS: Expanded Disability Status Scale; a Fisher’s exact test; b Mann-Whitney U test.
4.2. Blood Samples and PBMC Purification
Blood was collected in serum tubes (BD Biosciences, Oxford, UK) and centrifuged at 3000 rpm
for 10 min. Aliquots of serum were stored at −20 ◦C. PBMC were separated from heparinized whole
blood by density gradient centrifugation on Ficoll-Hypaque (GE Healthcare, Uppsala, Sweden) by the
standard procedure.
4.3. Measurement of Acetylcholine Levels
ACh was measured by commercial colorimetric/fluorimetric kit (Abcam, Cambridge, UK),
as previously reported [16]. The level of Ch/ACh (pmol/well) was calculated by plotting the
fluorescence of each sample in relation to choline standard curve. The measurement of the fluorescence
was obtained using Glomax Multi Detection System (Promega, Milano, Italy) at λ Ex/Em 535/587 nm.
4.4. Cholinesterase Activity Determination
Cholinesterase activities were measured in sera of RR-MS patients and HD by Ellman assay [41],
using 1 mM final concentration of acetyl-thiocholine iodide as substrate. In order to evaluate the
contribution of AChE and BuChE to the total cholinesterase activity, 1.4 × 10−5 M BW284c51 or
1.4 × 10−5 M lysivane were respectively added as appropriate inhibitors, in the reaction mixture
containing 0.33 mM DTNB (di-nitro-thiocyanobenzene) in 0.1 M phosphate buffer, pH 7.
Enzyme activity was expressed as mU; 1 mU corresponding to 1 nmole of substrate hydrolyzed/min
at 30 ◦C.
4.5. RNA Extraction, qRT-PCR and Semi-Quantitative RT-PCR Analysis
Total RNA was extracted from PBMC using Blood Total RNA purification kit (FMB, Italy) and
then digested with DNAse I (Ambion-Life Technologies Italia, Monza, Italy). One microgram of RNA
was reverse transcribed into cDNA according with the manufacturer’s instructions. Quantitative
real-time PCR were performed with GoTaq qPCR Master mix (Promega, Milano, Italy) using Cycler
IQTM Multicolor Real Time Detection System (Biorad, Hercules, CA, USA). Quantification of gene
expression was calculated using the comparative threshold cycle (Ct) method, normalized to the 18 S
control and efficiency of the RT reaction (relative quantity, 2−∆∆Ct). For semiquantitative RT-PCR
(sqRT-PCR) the densitometric analysis of the bands were performed using ImageJ software (Bethesda,
MA, USA) (OD amplicon/OD housekeeping gene). These values are expressed as arbitrary units.
The sequences of the primers used in RT-PCR analysis are reported in Table 4.
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Table 4. Primers sequences used in qRT-PCR and semiquantitative RT-PCR analysis.
Primers Sequences (qRT-PCR) Forward Reverse
AChE 5′-TCTACGCCTACGTCTTTGAA-3′ 5′-AACTCGATCTCGTAGCCGT-3′
BuChE 5′-TATGGGACTCCTTTGTCAGT-3′ 5′-TGAAGCCAGGAGCACCATA-3′
ChAT 5′-AGAGCAGCAGGAAGCTGAT-3′ 5′-TTTTCTGCCGAGGAGGCTAA-3′
IL-12/23 5′-CCGTTCACAAGCTCAAGTATG-3′ 5′-GCAGAATGTCAGGGAGAAGTAG-3′
IL-18 5′- CAGTCAGCAAGGAATTGTCTC-3′ 5′-GAGGAAGCGATCTGGAAGG-3′
TNFα 5′-CCTTCCTGATCGTGGCAG-3′ 5′-GCTTGAGGGTTTGCTACAAC-3′
18 S 5′-CCAGTAAGTGCGGGTCATAAGC-3′ 5′-AACGATCCAATCGGTAGTAGCG-3′
Primers Sequences (sqRT-PCR) Forward Reverse
OCTN-1 5′-CTGCCCAGGCGTTATATCAT-3′ 5′-GGTTGGGTAGAGCTCAGCAG-3′
Mediatophore 5′-TCCTCTCCACAAAGTAGACCCT-3′ 5′-TGTTCGTTCTGGAATGAGGA-3′
4.6. Cytokine Measurements
Human cytokine levels in serum were quantified using ELISA assays for IL-18, IL12/IL-23p40
and TNFα. ELISA assay was conducted with commercial kits (R & D System, Minneapolis, MN, USA)
according to the manufacturer’s instructions. The plates were read at 450 nm and the absorbance was
transformed to pg/mL, using calibration curves prepared with cytokine standards. The intra- and
inter-assay reproducibilities were >90%.
4.7. Statistical Analysis
The quantitative variables were summarized as mean, standard error (SEM) and interquartile
range (IQR), qualitative variables as frequency and percentage. The results are reported separately
for each of two groups (HD and RR-MS). Statistical analysis was performed using non-parametric
tests when the distribution of the variables was not normal, as assessed by the Shapiro-Wilk test.
Mann-Whitney U test was applied for assessing the comparison of the quantitative variables between
two groups. Fisher’s exact test was applied for comparison of the qualitative variables. The correlations
between serum ACh and other quantitative variables were estimated by non-parametric Spearman
rho correlation coefficient (σ). All statistical tests were evaluated at an alpha level of 0.05. Statistical
analysis was performed using SPSS® Advanced Statistical 11.0 software (SPSS Inc., Chicago, IL, USA).
5. Conclusions
For the first time we demonstrate an inverse correlation between cholinergic hydrolyzing enzyme
activity and ACh levels in serum of RR-MS patients. The present data suggest that the dysregulation of
ACh levels may contribute to the pathogenesis of MS, contributing to maintaining the pro-inflammatory
state. The reestablishment of the correct ACh homeostasis in the immune system of MS patients,
with the consequent regulation of pro-inflammatory cytokines, may be a new, interesting therapeutic
perspective for MS. Although, to date, there are not sufficient data in MS patients on the use of
AChE inhibitors [42,43], it is known that EAE mice chronically treated with AChE inhibitors present
amelioration of the disease symptoms and reduction of neuroinflammation and demyelination [27].
However, the possible activation of nicotinic receptors with selective agonists may represent a possible
alternative to the therapeutic modulation of the immune system in MS, as suggested by our previous
study, indicating the ability of nicotinic receptor agonists to decrease the pro-inflammatory cytokine
production in PBMC of MS patients [36].
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